Nothing Special   »   [go: up one dir, main page]

Dixon et al., 2021 - Google Patents

TIM-3 restrains anti-tumour immunity by regulating inflammasome activation

Dixon et al., 2021

View HTML
Document ID
3104816402326763584
Author
Dixon K
Tabaka M
Schramm M
Xiao S
Tang R
Dionne D
Anderson A
Rozenblatt-Rosen O
Regev A
Kuchroo V
Publication year
Publication venue
Nature

External Links

Snippet

T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a molecule expressed on interferon-γ producing T cells, is emerging as an important immune- checkpoint molecule, with therapeutic blockade of TIM-3 being investigated in multiple …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells

Similar Documents

Publication Publication Date Title
Dixon et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation
LaFleur et al. PTPN2 regulates the generation of exhausted CD8+ T cell subpopulations and restrains tumor immunity
Binnewies et al. Unleashing type-2 dendritic cells to drive protective antitumor CD4+ T cell immunity
Wang et al. Crosstalks between mTORC1 and mTORC2 variagate cytokine signaling to control NK maturation and effector function
Chen et al. CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy
Bod et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity
Raeber et al. Interleukin-2 signals converge in a lymphoid–dendritic cell pathway that promotes anticancer immunity
Craft Follicular helper T cells in immunity and systemic autoimmunity
Patel et al. The role of B lymphocytes in the immuno-biology of non-small-cell lung cancer
Okamura et al. TGF-β3-expressing CD4+ CD25− LAG3+ regulatory T cells control humoral immune responses
Delgoffe et al. Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
Moon et al. In vivo action of IL-27: reciprocal regulation of Th17 and Treg cells in collagen-induced arthritis
Ouyang et al. Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation
Shen et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases
Schmitt et al. The cytokine TGF-β co-opts signaling via STAT3-STAT4 to promote the differentiation of human TFH cells
Iwata et al. ICOSLG-mediated regulatory T-cell expansion and IL-10 production promote progression of glioblastoma
Doedens et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
Su et al. Tumor microenvironments direct the recruitment and expansion of human Th17 cells
Rudloff et al. Monocytes and dendritic cells are the primary sources of interleukin 37 in human immune cells
Reynolds et al. Toll-like receptor 2 signaling in CD4+ T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease
Ding et al. IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells
Choi et al. The lupus susceptibility gene Pbx1 regulates the balance between follicular helper T cell and regulatory T cell differentiation
Zhang et al. Type 1 conventional dendritic cell fate and function are controlled by DC-SCRIPT
Varga et al. Immune suppression via glucocorticoid-stimulated monocytes: a novel mechanism to cope with inflammation
Masuda et al. Sex‐based differences in CD103+ dendritic cells promote female‐predominant Th2 cytokine production during allergic asthma